Form 8-K Sagent Pharmaceuticals, For: Jun 09

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 9, 2015

 

 

Sagent Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

 

Commission File Number: 1-35144

 

Delaware		98-0536317
(State or other jurisdiction of incorporation)		(IRS Employer Identification No.)

1901 N. Roselle Road, Suite 700, Schaumburg, Illinois 60195

(Address of principal executive offices, including zip code)

(847) 908-1600

(Registrant’s telephone number, including area code)

 

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

---

Item 5.07. Submission of Matters to a Vote of Security Holders.

On June 9, 2015, Sagent Pharmaceuticals, Inc. (the “Company” or “we”) held our annual meeting of stockholders in Hoffman Estates, Illinois, at which three proposals were presented to the Company’s stockholders for consideration. The three proposals, each of which were described in the Company’s definitive Proxy Statement filed with the Securities and Exchange Commission on April 29, 2015 (the “Proxy Statement”), were: (1) to elect as Class I or Class III directors the nominees named in the Proxy Statement each to serve a one-year term and until their successors are duly elected and qualified, subject to earlier resignation, removal or death; (2) to ratify the retention of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2015; and (3) to hold an advisory vote to approve the compensation of the Company’s named executive officers. A total of 28,493,277 shares, or 88.80%, of our issued and outstanding shares of common stock as of April 15, 2015, were represented in person or by proxy at the annual meeting. The final results for each of the matters submitted to a stockholder vote at the annual meeting are as follows:

Proposal 1.

Our stockholders elected the Class I directors named below to serve a one-year term until our 2016 annual meeting of stockholders or until their successors have been duly elected and qualified, subject to their earlier resignation, removal or death. The votes regarding this proposal were as follows:

 

		For				Against				Abstain				Broker Non-Votes
Michael Fekete			21,992,153				0				5,048,735				1,452,389
Shlomo Yanai			20,920,168				0				6,120,720				1,452,389

Our stockholders elected the Class III director named below to serve a one-year term until our 2016 annual meeting of stockholders or until his successor has been duly elected and qualified, subject to his earlier resignation, removal or death. The votes regarding this proposal were as follows:

 

		For				Against				Abstain				Broker Non-Votes
Robert Flanagan			21,720,925				0				5,319,963				1,452,389

Proposal 2.

Our stockholders ratified the retention of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2015. The votes regarding this proposal were as follows:

 

For		Against		Abstain
27,493,431		828,823		171,023

Proposal 3.

Our stockholders approved, in an advisory vote, the compensation of our named executive officers. The votes regarding this proposal were as follows:

 

For		Against		Abstain		Broker Non-Votes
25,939,684		928,886		172,318		1,452,389

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

						SAGENT PHARMACEUTICALS, INC.
Date: June 11, 2015						/S/    MICHAEL LOGERFO
				Name:		Michael Logerfo
				Title:		President, Chief Legal Officer and Corporate Secretary

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• TD Bank Group and Aga Khan Museum Renew Collaboration for An Additional Three Years
• Solaris Reports First Drilling Results from 2024 Program and Exploration Update, Including 150m of 0.67% CuEq within 384m of 0.51% CuEq and 284m of 0.53% CuEq from Near Surface
• Dunes Point Capital, LP has sold the manufacturing business of Harvey Building Products to Cornerstone Building Brands